Newsroom
The Latest News From the Ivy Center
The Ivy Brain Tumor Center at Barrow Neurological Institute strives to be a valuable resource for any brain tumor or brain cancer-related media needs. Our media relations team is happy to help answer questions and arrange interviews. The expert neurosurgeons, neuro-oncologists and scientists at the Ivy Center are available to speak on a variety of topics.
Our state-of-the-art media studio is available for audio and video interviews. We can also arrange filming opportunities at various locations around the center and labs.
To contact the media relation team, call 602-406-7437 or email: [email protected].
Please see below for the latest media coverage and news from the Ivy Center. To read about our inspiring patients and those behind the scenes at the Ivy Center, visit the Ivy Blog.
3 Questions on Phase 0 Clinical Trials for Brain Tumors
The Ivy Brain Tumor Center at the Barrow Neurological Institute is a nonprofit center conducting early phase clinical trials of new therapeutics for brain tumors. In this interview with Oncology Times, Dr. Nader Sanai explains how the phase 0 trials work and why the center is so excited about them.
Ivy Brain Tumor Center Expands Phase 0 Clinical Trials Program to the East Valley
The Ivy Brain Tumor Center at Barrow Neurological Institute has announced a partnership with two East Valley hospitals to expand its novel Phase 0 clinical trials program, the first of its kind in neuro-oncology.
Woman of the Week Podcast: Catherine Ivy
Catherine Ivy, who lost her husband a decade ago to a devastating and sudden brain cancer, shares her personal journey of grief and purpose, which led to the founding of the Ivy Brain Tumor Center at the Barrow Neurological Institute.
Cancer Today Magazine cover story features Lanette Veres of the Gray Matters Foundation
Brain cancer survivor Lanette Veres sends cards and packages to others with the disease. She believes no one should face cancer alone.
Catherine Ivy: A Tireless Advocate for Brain Cancer Patients
In this edition of The Onco’Zine Brief, Peter Hofland talks with Catherine Ivy about how after losing her husband Ben to glioblastoma she became a tireless advocate for brain cancer patients.
First-in-human Study to Determine Effectiveness of Novel, Non-invasive Therapy for Brain Cancer
The Ivy Brain Tumor Center at the Barrow Neurological Institute and SonALASense have signed an strategic agreement to jointly test a new and non-invasive drug-device combination, called sonodynamic therapy or SDT, for the treatment of recurrent glioblastoma.
Ivy Brain Tumor Center and SonALAsense to Test Novel Drug-Device Combination for Glioblastoma
The Ivy Brain Tumor Center at the Barrow Neurological Institute, today announced a strategic collaboration with SonALASense to develop and test a new, non-invasive drug-device combination, sonodynamic therapy (SDT), for recurrent glioblastoma through a Phase 0/2 clinical trial.
Philanthropist Funds Personalized Research Program For Brain Cancer
Catherine Ivy sat down with Devin Thorpe's Your Mark On The World to discuss her personal fight with glioblastoma and how she hopes to shake up the research process with her investment in the Ivy Center's Phase 0 clinical trials.
Ivy Brain Tumor Center And BridgeBio Subsidiary QED Therapeutics Announce Collaboration To Advance Cancer Research And Treatment Options
The Ivy Brain Tumor Center at Barrow Neurological Institute, today announced a new collaboration with QED Therapeutics, Inc., a subsidiary of BridgeBio Pharma, Inc., to investigate the FGFR1-3 tyrosine kinase inhibitor, infigratinib, for the treatment of glioblastoma (GBM).
Social Impact Heroes: “Why Catherine Ivy and the Ivy Foundation have contributed over $91 million to accelerate drug and treatment discovery for brain cancer”
Catherine Ivy was recently interviewed for Authority Magazine's latest "Social Impact Heroes" series where she opened up about her 14-year journey to accelerate drug discovery for brain tumor patients, a recent success story from the Ivy Center's Phase 0 clinical trials program, and what our community, society and politicians can do to help address the unmet needs of patients battling aggressive brain tumors.